J.Safra Asset Management Corp Akero Therapeutics, Inc. Transaction History
J.Safra Asset Management Corp
- $1.31 Billion
- Q2 2025
A detailed history of J.Safra Asset Management Corp transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, J.Safra Asset Management Corp holds 6 shares of AKRO stock, worth $316. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6Holding current value
$316% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AKRO
# of Institutions
275Shares Held
85.7MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$392 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$373 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$313 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$295 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$276 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.45B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...